PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2019 • Market size and forecast 2019-2024 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE ANALYSIS PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Hemophilia A - Market size and forecast 2019-2024 • Hemophilia B - Market size and forecast 2019-2024 • Von Willebrand disease - Market size and forecast 2019-2024 • Other disorders - Market size and forecast 2019-2024 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2019-2024 • Europe - Market size and forecast 2019-2024 • Asia - Market size and forecast 2019-2024 • ROW - Market size and forecast 2019-2024 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • R&D of novel therapies • Emergence of gene therapy • Advent of bispecific antibodies PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Baxter International Inc. • Bayer AG • CSL Ltd. • F. Hoffmann-La Roche Ltd. • Grifols SA • Novo Nordisk AS • Octapharma AG • Pfizer Inc. • Sanofi • Takeda Pharmaceutical Co. Ltd. PART 15: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2019 Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions) Exhibit 09: Global market: Year-over-year growth 2020-2024 (%) Exhibit 10: Five forces analysis 2019 Exhibit 11: Five forces analysis 2024 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2019 Exhibit 18: Late-stage pipeline Exhibit 19: Type - Market share 2019-2024 (%) Exhibit 20: Comparison by type Exhibit 21: Hemophilia A - Market size and forecast 2019-2024 ($ millions) Exhibit 22: Hemophilia A - Year-over-year growth 2020-2024 (%) Exhibit 23: Hemophilia B - Market size and forecast 2019-2024 ($ millions) Exhibit 24: Hemophilia B - Year-over-year growth 2020-2024 (%) Exhibit 25: Von Willebrand disease - Market size and forecast 2019-2024 ($ millions) Exhibit 26: Von Willebrand disease - Year-over-year growth 2020-2024 (%) Exhibit 27: Other disorders - Market size and forecast 2019-2024 ($ millions) Exhibit 28: Other disorders - Year-over-year growth 2020-2024 (%) Exhibit 29: Market opportunity by type Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2019-2024 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2019-2024 ($ millions) Exhibit 34: North America - Year-over-year growth 2020-2024 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2019-2024 ($ millions) Exhibit 37: Europe - Year-over-year growth 2020-2024 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2019-2024 ($ millions) Exhibit 40: Asia - Year-over-year growth 2020-2024 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2019-2024 ($ millions) Exhibit 43: ROW - Year-over-year growth 2020-2024 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Impact of drivers and challenges Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: Baxter International Inc. - Vendor overview Exhibit 54: Baxter International Inc. - Business segments Exhibit 55: Baxter International Inc. - Organizational developments Exhibit 56: Baxter International Inc. - Geographic focus Exhibit 57: Baxter International Inc. - Segment focus Exhibit 58: Baxter International Inc. - Key offerings Exhibit 59: Baxter International Inc. - Key customers Exhibit 60: Bayer AG - Vendor overview Exhibit 61: Bayer AG - Business segments Exhibit 62: Bayer AG - Organizational developments Exhibit 63: Bayer AG - Geographic focus Exhibit 64: Bayer AG - Segment focus Exhibit 65: Bayer AG - Key offerings Exhibit 66: Bayer AG - Key customers Exhibit 67: CSL Ltd. - Vendor overview Exhibit 68: CSL Ltd. - Business segments Exhibit 69: CSL Ltd. - Organizational developments Exhibit 70: CSL Ltd. - Geographic focus Exhibit 71: CSL Ltd. - Segment focus Exhibit 72: CSL Ltd. - Key offerings Exhibit 73: CSL Ltd. - Key customers Exhibit 74: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 75: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 76: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 77: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 78: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 79: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 80: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 81: Grifols SA - Vendor overview Exhibit 82: Grifols SA - Business segments Exhibit 83: Grifols SA - Organizational developments Exhibit 84: Grifols SA - Geographic focus Exhibit 85: Grifols SA - Segment focus Exhibit 86: Grifols SA - Key offerings Exhibit 87: Grifols SA - Key customers Exhibit 88: Novo Nordisk AS - Vendor overview Exhibit 89: Novo Nordisk AS - Business segments Exhibit 90: Novo Nordisk AS - Organizational developments Exhibit 91: Novo Nordisk AS - Geographic focus Exhibit 92: Novo Nordisk AS - Segment focus Exhibit 93: Novo Nordisk AS - Key offerings Exhibit 94: Novo Nordisk AS - Key customers Exhibit 95: Octapharma AG - Vendor overview Exhibit 96: Octapharma AG - Organizational developments Exhibit 97: Octapharma AG - Key offerings Exhibit 98: Octapharma AG - Key customers Exhibit 99: Pfizer Inc. - Vendor overview Exhibit 100: Pfizer Inc. - Business segments Exhibit 101: Pfizer Inc. - Organizational developments Exhibit 102: Pfizer Inc. - Geographic focus Exhibit 103: Pfizer Inc. - Segment focus Exhibit 104: Pfizer Inc. - Key offerings Exhibit 105: Pfizer Inc. - Key customers Exhibit 106: Sanofi - Vendor overview Exhibit 107: Sanofi - Business segments Exhibit 108: Sanofi - Organizational developments Exhibit 109: Sanofi - Geographic focus Exhibit 110: Sanofi - Segment focus Exhibit 111: Sanofi - Key offerings Exhibit 112: Sanofi - Key customers Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 116: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 119: Validation techniques employed for market sizing Exhibit 120: Definition of market positioning of vendors

Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.